| |
 |
Pfizer Inc. Patents |
|
Assignee: Pfizer Inc.
Address: New York, NY
No. of patents: 3454
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| RE40838 |
2-azabicyclo[3.3.1]nonane derivatives |
July 7, 2009 |
| The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly |
| RE39558 |
5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating |
April 10, 2007 |
| Compounds of this formula ##STR00001## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. |
| RE39419 |
Estrogen agonist/antagonist metabolites |
December 5, 2006 |
| This invention relates to compounds that are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd- ro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemi |
| RE39149 |
Method of administering azithromycin |
June 27, 2006 |
| An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages c |
| RE38524 |
Dipeptide derivatives as growth hormone secretagogues |
June 1, 2004 |
| This invention is directed to compounds of the formula ##STR1##and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compound |
| RE35865 |
Preparation of glutaric acid derivatives |
July 28, 1998 |
| The Invention provides a process for preparing a compound of the formula: ##STR1## or a base salt thereof, wherein R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl optionally substituted by up to 3 substituents each independently selected from the group consisting of C.sub.1 -C.sub.6 al |
| RE29669 |
Production of 4-hydroxy-1,2-benzothiazine-3-carboxamides |
June 13, 1978 |
| A process for the synthesis of N-aryl-3,4-dihydro-2-alkyl-4-oxo-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides by treatment of N-aryl-N'-alkyl-N'-(2'-alkoxycarbonylbenzenesulfonyl)glycineamides, useful intermediates for said process, with an alkali or alkaline earth metal hydrid |
| RE29668 |
Glycineamides |
June 13, 1978 |
| A process for the synthesis of N-aryl-3,4-dihydro-2-alkyl-4-oxo-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides by treatment of N-aryl-N'-alkyl-N'-(2'-alkoxycarbonylbenzenesulfonyl)glycineamides, useful intermediates for said process, with an alkali or alkaline earth metal hydrid |
| D499023 |
Liquid measuring vessel |
November 30, 2004 |
|
| D450153 |
Applicator |
November 6, 2001 |
|
| D444056 |
Blister package dispenser |
June 26, 2001 |
|
| D440871 |
Blister package |
April 24, 2001 |
|
| D437407 |
Pharmaceutical tablet |
February 6, 2001 |
|
| D434136 |
Pharmaceutical tablet |
November 21, 2000 |
|
| D434135 |
Pharmaceutical tablet |
November 21, 2000 |
|
| D433750 |
Pharmaceutical tablet |
November 14, 2000 |
|
| D433501 |
Pharmaceutical tablet |
November 7, 2000 |
|
| D433500 |
Pharmaceutical tablet |
November 7, 2000 |
|
| D433499 |
Pharmaceutical tablet |
November 7, 2000 |
|
| D433122 |
Pharmaceutical tablet |
October 31, 2000 |
|
| D433121 |
Pharmaceutical tablet |
October 31, 2000 |
|
| D432714 |
Applicator |
October 24, 2000 |
|
| D432641 |
Pharmaceutical tablet |
October 24, 2000 |
|
| D431093 |
Applicator |
September 19, 2000 |
|
| D430703 |
Applicator |
September 5, 2000 |
|
| D415272 |
Pharmaceutical tablet |
October 12, 1999 |
|
| D414552 |
Pharmaceutical tablet |
September 28, 1999 |
|
| D414551 |
Pharmaceutical tablet |
September 28, 1999 |
|
| D414259 |
Pharmaceutical tablet |
September 21, 1999 |
|
| D413973 |
Pharmaceutical tablet |
September 14, 1999 |
|
| D413972 |
Pharmaceutical tablet |
September 14, 1999 |
|
| D410842 |
Bottle protecting container |
June 8, 1999 |
|
| D400434 |
Combined liquid measuring vessel and bottle |
November 3, 1998 |
|
| D392562 |
Blister pack |
March 24, 1998 |
|
| D363430 |
Container having a curved back panel |
October 24, 1995 |
|
| D353225 |
Nit comb |
December 6, 1994 |
|
| D336540 |
Nit comb |
June 15, 1993 |
|
| D311867 |
Cosmetic and perfume bottle |
November 6, 1990 |
|
| D308428 |
Cosmetic case |
June 5, 1990 |
|
| D286137 |
Combined pill dispenser and cover |
October 14, 1986 |
|
| D273704 |
Orthopedic surgery brush |
May 1, 1984 |
|
| D263172 |
Pharmaceutical tablet |
February 23, 1982 |
|
| D251823 |
Folding garden tool |
May 15, 1979 |
|
| D245316 |
Liquid dispenser |
August 9, 1977 |
|
| 7622605 |
Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments us |
November 24, 2009 |
| The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The pres |
| 7622589 |
Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists |
November 24, 2009 |
| This invention provides a compound of the formula (I): ##STR00001## wherein, variables A, B, D, E, and R.sup.1 to R.sup.11 are as defined in the specification. |
| 7622475 |
EP2 agonists |
November 24, 2009 |
| The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma. |
| 7618996 |
Diaryl ether derivatives and uses thereof |
November 17, 2009 |
| Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. ##STR00001## where R.sup.1, R.sup.2, R.sup.3, |
| 7618972 |
Substituted triazole derivatives as oxytocin antagonists |
November 17, 2009 |
| The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas inc |
| 7618797 |
Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) vir |
November 17, 2009 |
| The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American P |
|
|
|
